Drug Discovery
By
Can Gilead’s Twice-Yearly Yeytuo® (Lenacapavir) Redefine HIV Prevention Across Europe With Zero Infections in Phase 3 Trials?
Key Insights: A Historic European Approval That Expands Prevention Choices The European Commission granted marketing authorization for Gilead’s…
Can Amgen and Kyowa Kirin’s Rocatinlimab Redefine Atopic Dermatitis Care With Long-Term Safety and Sustained Efficacy in Over 2,600 Patients?
Key Insights: Breakthrough Data From ASCEND Long-Term Extension Amgen and Kyowa Kirin released top-line results from the global…
Lilly’s Jaypirca Shows Strong Phase 3 Results in Untreated CLL/SLL
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 BRUIN CLL-313 trial evaluating…
Could Immix Biopharma’s Strategic Investment by Goose Capital Accelerate Breakthrough CAR-T Therapies for AL Amyloidosis?
Key Highlights: Strategic Investment Signals Confidence in Immix’s Mission Immix Biopharma (Nasdaq: IMMX), a clinical-stage biopharma innovator, has…
Could Roche’s Giredestrant Become the New Standard for Early-Stage ER-Positive Breast Cancer?
Basel, Switzerland – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the Phase III lidERA…
Could GSK’s Twice-Yearly Asthma Drug Change Long-Term Treatment for Patients?
United States GlaxoSmithKline (GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved its new…
